$ATNM News

Last published 1d ago

1d agoATNMActinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha RadiotherapyPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies,...
2d agoATNMActinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting RadiotherapyPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the...
4d agoATNMActinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical DevelopmentPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies,...
1w agoATNMActinium Pharmaceuticals Announces Inducement Grant to New EmployeePR NewswireNEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement
3w agoATNMActinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026PR NewswireFirst‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapyHER3‑targeted alpha
3w agoATNMActinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate CancerPR NewswireHER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day
3w agoATNMActinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer ModelsPR NewswireATNM-400 demonstrated activity across EGFR-, KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established treatmentsIn colorectal cancer, adding
3w agoATNMActinium Pharmaceuticals Announces Inducement Grants to New EmployeesPR NewswireNEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement
4w agoATNMActinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer ModelsPR NewswireOral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic developmentColorectal cancer data
4w agoATNMActinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business DevelopmentPR Newswire– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals and BWXT Medical–
4w agoATNMActinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate CancerPR NewswireEarly clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC)Evaluation of
4w agoATNM CRMD OVIDActinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPR NewswireNEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment
2mo agoATNMActinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
3mo agoATNMActinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing UpdatePR NewswireNEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A
5mo agoATNMActinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung CancerPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on June 2,...
5mo agoATNMActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer ModelsPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on June 2,...
5mo agoATNM CNTAActinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline DevelopmentPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
5mo agoATNMActinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 RadioconjugatesPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on May 31,...
5mo agoATNMActinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT ProgramsPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...
5mo agoATNMActinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards NoticePR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...
6mo agoATNMActinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate OptimizationPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
6mo agoATNMActinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual MeetingPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
6mo agoATNMActinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual MeetingPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
7mo agoATNMActinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual MeetingPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
8mo agoATNMActinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual MeetingPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted...
11mo agoATNMActinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025PR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced the...
11mo agoATNMActinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer SymposiumPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced...
1y agoATNMActinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor IndicationsPR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted...
1y agoATNMActinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat ConferencePR NewswireActinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted...
1y agoATNMActinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted...
1y agoATNMActinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific RetreatPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted...
1y agoATNMActinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the ...
1y agoATNMActinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific RetreatPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted...
1y agoATNMActinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals SummitPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
1y agoATNMActinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual MeetingPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum: Now Available for Online ViewingGlobeNewswireNEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and
1y agoADIA ATNM BPTH CNVIF+12Life Sciences Investor Forum Agenda Announced for June 11th-12thGlobeNewswireNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is
1y agoATNMKuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE:...
1y agoATNMThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNMPR NewswireThe Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of...
1y agoATNMATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
1y agoATNMThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNMGlobeNewswireNEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE:ATNM). Shareholders who purchased shares of ATNM during the class
1y agoATNMKuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law FirmGlobeNewswireNEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) breached their
1y agoATNMINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options If you suffered losses
1y agoATNMActinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 27, 2025 to Discuss Your Rights - ATNMPR NewswireThe Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of...
1y agoATNMActinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical CenterPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
1y agoATNMATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLPGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options If you suffered losses
1y agoATNMThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNMGlobeNewswireNEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE:ATNM). Shareholders who purchased shares of ATNM during the class
1y agoATNMActinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual MeetingPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
1y agoATNMActinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual MeetingPR NewswireActinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today...
1y agoATNMThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNMPR NewswireThe Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of...